Analysts' Actions: Cisco, Office Depot, Pharmacyclics, Staples

NEW YORK (TheStreet) -- RATINGS CHANGES

Bonanza Creek (BCEI) was upgraded at Topeka Capital to buy from hold. Twelve-month price target is $68. Wattenberg acquisition should be highly accretive to earnings, Topeka Capital said.

Bio-Rad Laboratories (BIO) was downgraded to hold at TheStreet Ratings.

Cepheid (CPHD) was upgraded at Needham to buy from hold. Twelve-month price target is $50. More positive on the company, following meetings with management, Needham said.

Cisco (CSCO) was upgraded at Deutsche Bank to buy from hold. Twelve-month price target is $30. See stronger-than-anticipated business ramp, Deutsche Bank said.

CIT Group (CIT) was downgraded to sell at TheStreet Ratings.

Guidewire (GWRE) was upgraded at Citigroup to neutral. Twelve-month price target is $43. Expectations have come in and company fundamentals are improving, Citigroup said.

Office Depot (ODP) was upgraded at Goldman Sachs to buy from neutral. Twelve-month price target is $7. Company can likely exceed consensus earnings expectations, Goldman Sachs said.

Palo Alto (PANW) was upgraded at Nomura to buy from neutral. Twelve-month price target is $80. See fewer risks around the Juniper litigation, Nomura said.

Pharmacyclics (PCYC) was downgraded at RBC Capital to sector perform from outperform. Twelve-month price target is $95. Company is facing potential growth headwinds, RBC Capital said.

Staples (SPLS) was downgraded at Goldman Sachs to sell. Twelve-month price target is $11. Company is facing margin pressure, Goldman said.

Editor's note: To see analysts' stock comments and changes to price targets and earnings estimates, go to "Street Notes" which is available only to Real Money subscribers. To find out how to become a subscriber, please click here.

Follow TheStreet on Twitter and become a fan on Facebook.

>>Read More: Apple Annihilates Android, Crushes Stock Market in 2015

>>Read More: Apple's 'Smart Home' Levels Android All Over Again

This article was written by a staff member of TheStreet.

More from Stocks

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says